• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
138834 165 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
! a2 o/ p5 X- v2 \$ m: a+ L
可以,但要有针对性,
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
9 C0 S3 r1 o, ^. C  Q5 }
' d3 P  L  C  F3 D+ \; D
' w! `5 z4 A) Y% U8 `2 J# tSub-category:& ]; Y. M& l* }0 o1 W6 q% l* d# Q/ B- K
Molecular Targets 7 m* _5 k) o5 V
  D/ J- X1 L1 t  r! k5 ^

* p6 ~- f* I  k! A, qCategory:& ]( C; \5 b( q; m) O
Tumor Biology   i- W1 ~, E0 |3 f& }3 A  P

; R9 q0 r. |' U9 _4 v! P3 n7 M, z0 c
6 @. G, [# ^- J0 @  RMeeting:
8 H9 g7 T' Z- s1 X2011 ASCO Annual Meeting / Q, P, E  G6 B1 P- e

/ t) l' y, n) t3 F* _* [+ n) f5 k9 B) T2 `4 ~4 O3 J
Session Type and Session Title:3 J' l7 ~# w5 S) [) I
Poster Discussion Session, Tumor Biology
$ {5 g) |1 b8 O$ m$ y- @1 p8 @" R0 N
2 r+ o. w  t- Q) t, ^% d; a
Abstract No:. _" q9 B% j( C8 |$ U2 {
10517 3 @8 `  S- ~4 i! @
/ \% \% a+ k# I6 n& {  S: L
; `+ P& r+ l% @* U
Citation:
2 u; q# G" T2 O& c3 kJ Clin Oncol 29: 2011 (suppl; abstr 10517)
$ A) i# y' s( R3 O. j8 v
* s+ R7 Z, w! c% E# U- A; A4 r, ?) p+ i( e! N7 B5 s7 P: f
Author(s):
( X0 p7 x) |1 aJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China ! w; T! `- T# c
: O3 [) C. F: C+ F# R$ X

9 K: ^: M  `" b& _7 F8 D; r; \! |
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.# N4 H8 e; j: D/ r5 F- h* E  X( K! @' N
+ c* q2 E$ f/ \  ~& B1 [
Abstract Disclosures
8 Z, ^/ `1 f+ x3 }# a% q( j+ j, q& K
Abstract:5 h/ U% e& |+ _5 C4 D

* S& l4 ]$ _  S& `& j
3 r0 B6 S+ i. v: P+ sBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
7 u+ X; c0 \; d" C: i
. b+ ?/ P( L$ @- C" x% A
# l/ [5 o% n; c/ J
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37 0 o( @: p) V- _) O
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
* N1 E( O, {; |& _; y
化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20
  \. I8 X, X8 z! v; H易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。% ^" E  F; r) o5 F1 s5 \$ o
ALK一个指标医院要900多 ...
/ `/ z4 W4 Z7 {; @7 p3 n6 i. V
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?3 k! r0 _9 [. f

7 P/ b3 j3 h1 V) b( C3 v现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表